Pomeroy, Jeremy http://orcid.org/0000-0002-5270-9981
VanWormer, Jeffrey J.
Meilahn, Jill R.
Maki, Tara
Murali, Hema R.
Haws, Robert M.
Funding for this research was provided by:
Bardet-Biedl Syndrome Foundation
Article History
Received: 22 February 2021
Accepted: 7 June 2021
First Online: 14 June 2021
Declarations
:
: This study was approved by the Marshfield Clinic Research Institute Institutional Review Board. Individuals were recruited for participation in the research via telephone, and consent was provided verbally by the participant or their legal guardian.
: All individuals have been informed and agreed for this publication of aggregate data. No identifiable information, images, or videos of patients are included into this work.
: Robert Haws, MD is a consultant for Rhythm Pharmaceuticals and Axovia Therapeutics. He is a principal investigator for the Setmelanotide Phase 2 Treatment of Obesity in Rare Genetic Disorders. (ClinicalTrials.gov Identifier: NCT03013543); Setmelanotide (RM‐493), Melanocortin‐4‐Receptor Agonist, in Bardet‐Biedl Syndrome and Alström Syndrome Patients with Moderate to Severe Obesity (ClinicalTrials.gov Identifier NCT03746522) sponsored by Rhythm Pharmaceuticals and a principal investigator for A Research Study on How Well Semaglutide Works in Adolescents with Overweight or Obesity (ClinicalTrials.gov Identifier: NCT04102189) sponsored by Novo Nordisk Pharmaceuticals. Jeremy Pomeroy has received research support from Rhythm Pharmaceuticals as a co‐investigator for the Setmelanotide Phase 2 Treatment of Obesity in Rare Genetic Disorders. (ClinicalTrials.gov Identifier: NCT03013543). No other COI is declared.